Claims of the Application:

1. (Currently amended) A pharmaceutical dosage form comprising a tablet comprising a drug substance that is susceptible to polymorphic conversion, the tablet having been formed by compression with forces sufficiently low to maintain the drug in its original polymorphic form.

2. (Currently amended) The ~~tablet~~ pharmaceutical dosage form according to claim 1, wherein the drug substance is amorphous.

3. (Currently amended) The ~~tablet~~ pharmaceutical dosage form according to claim 2, wherein no greater than about 10 weight percent of the amorphous drug substance is crystalline.

4. (Currently amended) The ~~tablet~~ pharmaceutical dosage form according to claim 1, wherein compression is conducted between about 0.2 and about 5 tons.

5. (Currently amended) The ~~tablet~~ pharmaceutical dosage form according to claim 1, wherein compression is conducted between about 0.2 and about 3 tons.

6. (Currently amended) The ~~tablet~~ pharmaceutical dosage form according to claim 1, wherein a maximum tablet dimension is about 3 mm.

7. (Currently amended) The ~~tablet~~ pharmaceutical dosage form according to claim 1, wherein a maximum tablet dimension is about 1 mm to about 3 mm.

. 8. (Currently amended) [[A]] The pharmaceutical dosage form ~~comprising a plurality of tablets prepared according to~~ of claim 1, comprising a plurality of tablets contained within a capsule.

9. (Currently amended) [[A]] The pharmaceutical dosage form of claim 1, comprising a plurality of ~~particles~~ tablets formed by:

(a) mixing a drug substance that is susceptible to polymorphic conversion, with one or more pharmaceutically acceptable excipients;

(b) compressing the mixture at about 0.2 tons to about 5 tons pressure, to form ~~particles~~ tablets; and

(c) filling a plurality of the ~~particles~~ tablets into a capsule.

10. (Original) The pharmaceutical dosage form according to claim 9, wherein the drug substance is amorphous.

11. (Original) The pharmaceutical dosage form according to claim 9, wherein no greater than about 10 weight percent of the drug substance is crystalline.

12. (Original) The pharmaceutical dosage form according to claim 9, wherein compressing is conducted at about 0.2 tons to about 3 tons.

13. (Currently amended) The pharmaceutical dosage form according to claim 9, wherein a maximum ~~particle~~ tablet dimension is about 3 mm.

14. (Currently amended) A method of preparing ~~a~~ the pharmaceutical dosage form of claim 1, comprising:

(a) forming a mixture comprising a drug substance that is susceptible to polymorphic conversion, with one or more pharmaceutically acceptable excipients; and

(b) compressing the mixture at about 0.2 tons to about 5 tons pressure, to form ~~particles~~ tablets.

15. (Currently amended) The method according to claim 14, wherein ~~particles~~ tablets have a maximum dimension no greater than about 3 mm

16. (Original) The method according to claim 14, wherein the drug is amorphous.

17. (Currently amended) The method according to claim 14, further comprising applying a coating to the ~~particles~~ tablets.

18. (Original) The method according to claim 14, wherein compression is conducted at about 0.2 tons to about 3 tons.

19. (Original) The method according to claim 14, wherein a maximum dimension is about 1 mm to about 3 mm.

20. (Currently amended) The method according to claim 14, further comprising placing a plurality of ~~particles~~ tablets into a capsule.

21. (Currently amended) The ~~tablet~~ pharmaceutical dosage form according to claim 1, wherein a drug substance comprises esomeprazole magnesium.

22. (Previously presented) The pharmaceutical dosage form according to claim 9, wherein a drug substance comprises esomeprazole magnesium.

23. (Previously presented) The method according to claim 14, wherein a drug substance comprises esomeprazole magnesium.